Characterize and Assess Clinical Outcomes of Patients Receiving Tezepelumab After Marketing Approval in Spain
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
420actual
Sites
12
Country
Spain
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-06-23 | actual | When the study began enrolling |
| Primary completion | 2025-12-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-12-19 | actual | The whole study's end, after follow-up |
| First posted | 2025-06-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Asthma
Primary outcomes
what the primary-completion date above is the date OFSocio-demographic variables: Age (years), Gender (male, female, other); Smoking status (Current smoker, Ex- smoker, Non-smoker) and cumulative index (packs/year); Height (cm) and weight (kg); Body Mass Index (BMI) (kg/m 2 )
measured Index date (treatment initiation with tezepelumab)
Exacerbation (number of exacerbations)
measured From 12 months before index date (defined as the date of treatment initiation with tezepelumab) until the end of the follow up which will start after index date and will last up to inclusion (the period will last 9-15 months depending on inclusion date)
Comorbidities (e.g., allergic rhinitis, nasal polyposis, gastroesophageal reflux, chronic obstructive pulmonary disease (COPD), atopic dermatitis and other eosinophilic conditions, conditions related to OCS chronic use, etc.)
measured From 12 months before index date until index date (defined as the date of treatment initiation with tezepelumab)
Number of respiratory infections and diseases in the previous 12 months and index date
measured From 12 months before index date until index date (defined as the date of treatment initiation with tezepelumab)
Number of participants with an Allergy test (Prick test, RAST or similar, clinical relevance of allergy, etc.) (only baseline)
measured Only on the baseline (12 months prior to Index date)
Publications
- PMID 42379714 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed